US pharma company Avior Bio has agreed to acquire Sono-Tek ultrasonic coating equipment in a transaction based on cash and equity to advance kidney disease treatment, as per the latest medical device industry news.

Sono-Tek ultrasonic spray systems are based on proprietary ultrasonic nozzle technology and are used for a range of spray applications such as implantable medical device coatings.

Avior Bio will leverage Sono-Tek ultrasonic coating equipment in its product development and future manufacturing process.

The clinical stage pharma company has developed a patent-pending, nanoparticle based, sublingual delivery technology called Speedit and its lead candidate – AV104 – is indicated for the treatment of chronic kidney disease associated pruritus (CKD-aP) and Prurigo Nodularis.

Dr Niraj Vasisht – CEO of Avior Bio said: “Sono-Tek is well known for its precision medical device coating machinery.

“Sono-Tek’s ultrasonic spray technology offers Avior the ability to make uniform and well controlled microparticles in support of our patent-pending Speedit technology.

“After working at Sono-Tek’s laboratory with their talented applications engineering team, and upon successful completion of our proof-of-concept trials, we are thrilled that this custom-designed coating machine will enable Avior’s clinical trial material manufacturing up to Phase II clinical program.

“Partnering with a long-established coating manufacturer and process application experts will help to expedite our product and process development timelines.”

Avior Bio is reportedly seeking approval of AV104 through an NDA submission in the second quarter of 2023 via a 505b2 regulatory roadmap.

R Stephen Harshbarger – president of Sono-Tek said: “Avior Bio is developing a powerful technology in the nano and microparticle drug delivery arena.

“The Speedit transmucosal film technology is unlike anything else Sono-Tek has seen among its customers, and Avior is using that technology to develop its first product in the target market of chronic kidney disease (CKD).

“We are excited to have Sono-Tek coating machinery used in the Speedit manufacturing process, and to be an early investor in Avior.”

Avior Bio’s investors include National Institute of Health, Quality Chemical Laboratories, and North Carolina Biotechnology Center (NCBC).

For more medical device industry news, keep following Pharma News Daily.

Related posts

• Opentrons launches fully automated thermocycler at $4,000 (0)
• CinDome Pharma begins phase 2 trial of gastroparesis drug CIN-102 (0)
• Genentech bags Rozlytrek FDA approval for two rare types of cancer (0)
• GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group (0)
• Gemini Therapeutics appoints Jason Meyenburg as CEO (0)
• Castle Creek to acquire cell and gene therapy company Fibrocell (0)
• FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint (0)
• Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD (0)
• Aytu BioScience to acquire Innovus Pharmaceuticals (0)
• Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m (0)

The post Avior Bio to advance kidney disease treatment through Sono-Tek ultrasonic coating equipment appeared first on PharmaNewsDaily.com.